News Headlines Article

Amgen heart failure drug deal is good news — but little more — for Cytokinetics
San Francisco Business Times

A deal between Amgen Inc. and French drug developer Les Laboratoires Servier for a heart failure treatment provides validation for drug developer Cytokinetics Inc. but nothing for Cytokinetics’ bottom line. Amgen (NASDAQ: AMGN), the world’s largest biotech company, said Tuesday that it gave Servier commercial rights in Europe for the experimental heart failure drug omecamtiv mecarbil.

Commands